嶺南股份(002717.SZ)聯合體中標13.11億元東莞東引運河流域樟村斷面綜合治理工程(污水管網完善工程第四標段)項目
格隆匯11月18日丨嶺南股份(002717.SZ)公佈,近日,公司收到東莞市城建工程管理局、江西銀信工程造價諮詢有限公司發出的《中標通知書》,確定公司與中國建築第五工程局有限公司作為聯合體為“東莞市東引運河流域樟村斷面綜合治理工程(污水管網完善工程第四標段)”的中標單位。
項目名稱:東莞市東引運河流域樟村斷面綜合治理工程(污水管網完善工程第四標段);中標價:約13.11億元(具體以合同簽訂金額為準);招標內容:東莞市東引運河流域樟村斷面綜合治理工程(污水管網完善工程第四標段)為常平、黃江、大朗片區。工期:320日曆天。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.